From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...

CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...

Global health company The Cigna Group (NYSE:CI) will release its fourth quarter 2024 financial results on Thursday, January ...

The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including ...

Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...

Salem Health and Regence BlueCross BlueShield of Oregon are returning to the negotiating table after almost 30,000 people ...

We recently published a list of 12 Best Safe Dividend Stocks for 2025. In this article, we are going to take a look at where ...

Three major drug middlemenneedlessly marked up generic drugs for cancer, HIV, and multiple sclerosis to generate $7.3 billion ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average ...